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ABSTRACT
Reliance on glycolysis is a characteristic of malignancy, yet the development of 
resistance to BRAF inhibitors in melanoma is associated with gain of mitochondrial 
function. Concurrent attenuation of oxidative phosphorylation and HIF-1α/PKM2-
dependent glycolysis promotes a non-apoptotic, iron- and oxygen-dependent cell 
death that we term ferroxitosis. The redox cycling agent menadione causes a robust 
increase in oxygen consumption, accompanied by significant loss of intracellular 
ATP and rapid cell death. Conversely, either hypoxic adaptation or iron chelation 
prevents menadione-induced ferroxitosis. Ectopic expression of K213Q HIF-1α mutant 
blunts the effects of menadione. However, knockdown of HIF-1α or PKM2 restores 
menadione-induced cytotoxicity in hypoxia. Similarly, exposure of melanoma cells to 
shikonin, a menadione analog and a potential PKM2 inhibitor, is sufficient to induce 
ferroxitosis under hypoxic conditions. Collectively, our findings reveal that ferroxitosis 
curtails metabolic plasticity in melanoma.
INTRODUCTION
Malignant cells exploit the normal adaptive 
mechanisms to survive and proliferate in limited oxygen 
environment found within the tumor parenchyma. 
Hypoxia-inducible factor 1α (HIF-1α) is a key 
transcription factor that facilitates adaptation to hypoxic 
conditions [1]. The levels of HIF-1α protein are tightly 
controlled by the availability of oxygen and iron, which 
activate prolylhydroxylases-mediated hydroxylation 
of HIF-1α and subsequent proteasomal degradation 
[2]. Hypoxic conditions or limited availability of iron 
enable stabilization of HIF-1α protein and consecutive 
transcriptional activation of genes responsible for 
glucose uptake and glycolysis [3, 4]. While increasing 
the glycolytic capacity of cells, HIF-1α also limits the 
functions of mitochondria by diminishing the supply 
of acetyl-coA and NADH [5]. Although HIF-1α is a 
critical transcription factor that regulates glycolysis and 
oxidative phosphorylation to promote cell survival, a cell 
death mechanism that inactivates this transcription factor 
remains unknown. 
Pyruvate kinase M2 (PKM2), an embryonic isoform 
predominantly expressed in malignant cells catalyzes the 
conversion of phosphoenolpyruvate to pyruvate. PKM2 
is a key determinant of aerobic glycolysis, also known 
as the Warburg effect, which is commonly observed in 
tumor cells [6]. Although initially it was thought that 
PKM2 is a cytoplasmic glycolytic enzyme, subsequent 
studies uncovered its non-canonical nuclear functions [7-
9]. ERK1/2-phosphorylated PKM2 translocates into the 
nucleus and promotes c-myc transcription in mediating 
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the Warburg effect and tumorigenesis [10]. These 
findings underscore the critical role for both nuclear and 
cytoplasmic functions of PKM2 in tumor progression. 
Melanomas invariably harbor mutations that 
constitutively activate the RAF-MEK-ERK pathway, 
leading to aggressive progression of the disease [11-13]. 
Disruption of the RAF-MEK-ERK signaling with BRAF 
or MEK inhibitors has shown significant clinical responses 
in the treatment of melanoma, yet the rapid development 
of resistance to these inhibitors presents a formidable 
challenge [14]. Although aerobic glycolysis supports 
tumor cell proliferation, increased mitochondrial mass and 
capacity enables melanoma cells to overcome the RAF-
MEK-ERK pathway blockade strategy [15-18]. Therefore, 
targeting metabolic reprogramming may provide effective 
clinical strategy. Here we report a novel iron- and oxygen-
dependent mechanism of cell death that is coupled to 
oxidative phosphorylation and HIF-1α/PKM2-dependent 
glycolysis in melanoma.
RESULTS AND DISCUSSION
Menadione, a vitamin K metabolite [19], is 
detectable in human and rodent tissues, although the 
physiological role remains unclear. We undertook a 
study to evaluate the cytotoxic effects of menadione on 
human melanoma cells harboring mutations in BRAF 
(MEL526), NRAS (MEL103) and wild-type BRAF/NRAS 
(SKMEL23), or normal human fetal lung (IMR90) and 
skin (BJ) fibroblasts. Menadione significantly reduced the 
viability of melanoma cells in a concentration-dependent 
manner with an EC50 of 20μM, whereas the viability of 
normal cells was unchanged (Figure 1A). Subsequently, 
several melanoma cell lines exposed to 20μM menadione 
showed a dramatic reduction in viability regardless of the 
RAF-MEK-ERK pathway mutations (Figure 1B). Results 
Figure 1: Menadione causes rapid cell death in melanoma cells. A) Normal human cells, including fetal lung (IMR90) and skin 
(BJ) fibroblast cells as well as melanoma cell lines SK23 (wild-type BRAF/NRAS), SKMEL103 (NRASQ61L) and MEL526 (BRAFV600E) 
were treated with 0-80µM menadione, and cell viability determined. Graphs show average values ± s.d. of technical triplicates from a 
representative experiment. B) Indicated melanoma cell lines were treated with 20µM menadione and cell viability assessed at different time 
points. C) Bright-field microscopy images of melanoma cells treated with H2O2, menadione (MEN), and etoposide. D) Cells treated as in c 
and cytotoxicity was measured by trypan blue exclusion staining (average of three independent experiments). E) MEL526 cells implanted 
NSG mice were treated with vehicle or menadione. Tumor volume measurements are shown. Plotted mean and SEM (n=4), (* < 0.05). 
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from dye-exclusion assays revealed that menadione, 
but not other pro-oxidants, promoted a robust cell death 
(Figure 1C,D). The in vivo relevance of these observations 
was ascertained in MEL526 cells xenografted to NSG 
mice where menadione significantly reduced tumor growth 
(Figure 1E). To test the possibility of p53 activation and 
involvement of autophagy, melanoma cells were treated 
with etoposide, H2O2, or menadione, and the cell extracts 
were examined by immunoblot. Menadione neither 
activated the p53 pathway nor induced autophagy (Figure 
S1). Caspase activity was unchanged by menadione, and 
pre-treatment with the pan-caspase inhibitor Z-VAD-
FMK did not prevent its cytotoxic effects (Figure S1). 
Consistent with these data, menadione did not alter the 
mitochondrial membrane potential (Movie S1). Inhibition 
of necroptosis with nectrostatin-1 also did not reduce 
menadione-mediated cell death, in accordance with 
fluorescent assays of cell membrane integrity (Figure S1). 
These results suggest that menadione causes a form of cell 
death distinct from apoptosis, autophagy and necrosis. 
To determine whether menadione-mediated cell 
death is linked to energetic catastrophe we used an 
ATP-coupled luminescence assay. Menadione exposure 
caused a dose-dependent depletion of ATP, with a nadir 
at 40μM (Figure 2A). These results were substantiated 
by HPLC-based biochemical analysis of total nucleotide 
from menadione-treated samples, which confirmed a 
dramatic reduction in ATP and GTP, with no change in 
the levels of other nucleotides (Figure 2B). Measurements 
of oxygen consumption rate (OCR) demonstrated that 
menadione caused a robust increase in OCR, far exceeding 
that of  the uncoupling agent 2,4-dinitrophenol (Figure 
2C). Furthermore, dihydroethidium (DHE) fluorescence 
assay verified menadione-induced production of 
superoxide (Figure 2D). Consistent with this observation, 
pretreatment of cells with anti-oxidants prevented the 
effects of menadione (Figure S2). These results suggest 
that menadione uncouples oxidative phosphorylation in 
promoting rapid cell death. 
Considering the critical role of mitochondria in 
regulation of intracellular iron, we hypothesized that 
menadione-induced cell death may involve iron. Perls’ 
Figure 2: Menadione enhances oxygen consumption and depletes intracellular ATP. A) Menadione promotes dose-
dependent decrease in intracellular ATP levels in melanoma cells. ATP levels determined by a luminescent cell-based assay; n=3. B) HPLC 
determination of total nucleotides from cells that are treated with 20µM of MEN or vehicle for 1.5 hours. C) Oxygen consumption rate 
(OCR) was measured on a Seahorse analyzer. Oligomycin (1µM), vehicle (ethanol) or menadione (10-40µM), 2,4-dinitrophenol (DNP, 
60µM), and a combination of rotenone (1µM) and antimycin A (1µM) were applied to Mel526 cells as indicated. Each data point represents 
mean OCR ± s.e. from 5 replicates. D) Superoxide levels measurements by DHE fluorescence in the presence of menadione.
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DAB stain [20] of menadione-treated cells indicated 
release of free iron (Figure S3). To test if iron chelation 
would block menadione-mediated cytotoxicity, cells 
were treated with menadione in the presence or absence 
of structurally unrelated iron chelators deferoxamine and 
ciclopirox olamine, and cell viability was determined. 
Iron chelation protected the cells from menadione 
(Figure 3A), an effect corroborated in dye-exclusion 
assays (Figure 3B). In addition, deferoxamine partially 
rescued menadione-induced loss of ATP (Figure 3C) and 
significantly blunted menadione-mediated increase in 
OCR (Figure 3D). Although menadione was cytotoxic 
to lung (H1299) and cervical cancer (C33a) cell lines, 
deferoxamine did not confer protection, suggesting that 
iron chelation is not sufficient to overcome the effects of 
menadione in these non-melanoma cell lines. Moreover, 
these results support the interpretation that the effects 
observed in melanoma cells are biological and not due to 
drug interactions (Figure S4). To test the involvement of 
known iron regulators, melanoma cells were depleted of 
ACO1, ACO2, ACO3, FTMT, FXN and MFI2, and cell 
viability in presence of menadione was determined (Figure 
S5). Depletion of these iron regulators did not significantly 
change the outcome of menadione-induced cytotoxicity. 
We propose that the mechanism of ferroxitosis is distinct 
from that of ferroptosis [21], as the latter does not produce 
mitochondrial ROS and there is no change in the levels 
of ATP. Collectively, these results suggest that menadione 
Figure 3: Iron chelation or hypoxic adaptation prevents the effects of menadione. A) Iron chelators deferoxamine (DEF) 
(100µM) and ciclopirox (CPX) (10µM) prevent menadione-induced cytotoxicity as determined by resazurin-based assays. B) Prevention 
of menadione-induced melanoma cell death by iron chelation was assessed by trypan blue exclusion assays. C) Iron chelation partially 
reverses ATP depletion caused by menadione. Asterisk denotes significant difference between MEN and MEN+DEF treated samples of the 
corresponding MEN concentration group. *P<0.01. The error bars denote s.d. (n=5). D) OCR measurements of cells exposed to vehicle 
(red), 20µM menadione, (blue), 100µM deferoxamine (DEF) (green), or DEF+menadione (black). Each data point represents mean OCR ± 
s.e. from 5 replicates. E) Hypoxic conditions (green) prevented the effects of menadione as opposed to normoxia (red). Indicated melanoma 
cell lines were exposed to different doses of menadione in 1% oxygen (green) or 20% oxygen (red) and cell viability quantified. Data shown 
as mean ±s.d. of technical triplicates from a representative experiment. F) Melanoma cells expressing control, shHIF-1α, or shARNT2 were 
treated with vehicle (blue) or MEN (red) in hypoxia. HIF-1α or ARNT2 depletion sensitized cells to MEN-mediated cytotoxicity under 
hypoxic conditions.
Oncotarget12698www.impactjournals.com/oncotarget
targets mitochondria to cause an iron- and oxygen-driven 
cytotoxic process that we term ferroxitosis. 
Iron chelators are commonly used as hypoxia 
mimetics [3]. This led to the consideration that hypoxia 
may block menadione-induced ferroxitosis. Menadione 
decreased cell viability in normoxia, yet this effect was 
completely blocked by hypoxia (1% O2), suggesting that 
reliance on maximal mitochondrial respiration is essential 
for menadione-induced cell death (Figure 3E). These 
results are consistent with the reported observations that 
the hypoxic transcription program limits acetyl-CoA 
availability for the TCA cycle and reduces the efficiency 
of electron transfer, thereby collectively minimizing 
mitochondrial function in hypoxic conditions [5, 22, 23]. 
To test whether hypoxia transcription factor HIF-1α is 
responsible for this protective effect, MEL526 cells were 
transduced with lentivirus encoding control, HIF-1α, or 
HIF-1α transcriptional subunit ARNT2 shRNAs, and 
exposed to menadione. Depletion of either HIF-1α or 
ARNT2 restored menadione sensitivity in hypoxia (Figure 
3F). These observations are in agreement with studies 
showing that HIF-1α-null mouse embryonic fibroblasts 
show elevated oxygen consumption and ATP production 
in hypoxia, revealing a reverse metabolic switch from 
glycolysis to oxidative phosphorylation [22, 24]. We 
conclude that activation of HIF-1α protects cells from 
menadione-induced ferroxitosis by minimizing oxidative 
phosphorylation, while attenuation of the HIF-1α pathway 
forces cells to use mitochondria for energy production, 
thereby restoring sensitivity to menadione.
Mining of the publicly available COSMIC cancer 
genome catalog (http://cancer.sanger.ac.uk/cosmic/
mutation/overview?id=1559432), which includes the 
data set from The Cancer Genome Atlas revealed a 
novel recurrent mutation, K213Q, in the dimerization 
domain of HIF-1α in human glioma samples (Table S1). 
While the HIF-1α oxygen sensing domain, where prolyl 
hydroxylases target P402 and P564 to promote degradation 
[25, 26], is relatively well-studied, the dimerization 
domain that harbors K213Q is not. We questioned 
whether the K213Q amino acid substitution may have an 
evolutionary significance. While lysine 213 of the HIF-
1α protein is highly conserved from humans to zebrafish, 
Antarctic deep-water fish Pachycara brachycephalum 
harbors glutamine instead of lysine at 213 (Figure 4A). 
Metabolic adaptation enables this fish to dwell in an 
oxygen-limited environmental niche [27]. Although 
publicly available dataset has not revealed the presence 
of K213Q mutation in melanoma samples, studies 
suggest that HIF-1α-dependent glycolytic program offers 
metabolic plasticity and growth advantage for melanoma 
cells [28-33]. To test the effects of K213Q on the stability 
of the HIF-1α protein, MEL526 cells were lentivirally 
transduced to express wild type HIF-1α, the degradation-
resistant P402A/P564A (HIF-1PA), K213Q (HIF-1Q), 
and the combined K213Q/P402A/P564A (HIF-1QPA). 
Immunoblot analysis showed an increase in the stability 
of the HIF-1PA and HIF-1QPA mutants (Figure 4B). To 
assess the biological effects of K213Q, melanoma cells 
stably expressing wild-type HIF-1α, HIF-1Q, HIF-1PA, 
or HIF-1QPA were exposed to menadione. Among these 
stable cells, an increased protection against menadione 
Figure 4: K213Q HIF-1α mutant attenuates the cytotoxic effects of menadione. A) Sequence alignment of HIF-1α protein 
showing conservation of K213. B) Schematic representation of HIF-1α, K213Q, P402A/P564A, or a combination of these mutations. 
Immunoblot showing relative levels of HIF-1α protein expression in melanoma cells transduced with indicated HIF-1α viral vectors. C) 
Overexpression of HIF-1QPA mutant but not the individual mutants enabled melanoma cells to resist MEN-induced cytotoxicity. Data 
shown as mean ± s.d. of technical triplicates from a representative experiment. D) OCR measurements show that HIF-1QPA expressing 
cells blunt the effects of menadione-induced increase in oxygen consumption. The error bars denote s.e.m. (n=5). 
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by HIF-1Q-expressing cells and a complete prevention of 
menadione-induced ferroxitosis by HIF-1QPA-expressing 
cells were recorded (Figure 4C). Therefore, we asked if 
HIF-1QPA would suppress the enhanced rate of oxygen 
consumption by menadione. We found that melanoma 
cells expressing HIF-1QPA reduced menadione-mediated 
increase in OCR by 50% compared to cells expressing wt-
HIF-1α (Figure 4D). These results lead us to propose that 
K213Q of HIF-1α found in tumor cells or organisms living 
in limited oxygen enable them to reduce mitochondrial 
respiration in adaptation to hypoxic conditions. 
To further characterize the mechanism of 
ferroxitosis, we screened analogs of menadione with 
the aim of identifying a compound possessing the anti-
mitochondrial activity of menadione while blunting the 
protective effects of iron chelation (Figure S6). One such 
compound, shikonin consistently reduced cell viability 
even in the presence of iron chelator. Shikonin has been 
Figure 5: Activation of ferroxitosis involves concurrent inhibition of oxidative phosphorylation and PKM2-dependent 
glycolysis in melanoma. A) MEL526 (BRAFV600E) or MEL103 (NRASQ61L) cells exposed to MEK inhibitor trametinib, BRAF inhibitor 
vemurafenib, menadione, shikonin, or a combination of these drugs as shown in normoxia or hypoxia, and cell viability measured. B) 
Indicated melanoma cells were transfected with control or PKM2 siRNA; treated with vehicle (blue) or MEN (red) in hypoxic conditions 
and cell viability assessed. C) OCR measurements of melanoma cells exposed to vehicle (DMSO) or shikonin, shikonin+DEF. Each data 
point represents mean OCR ± s.e. from 5 replicates. D) Western blot analysis of melanoma cells treated with menadione or shikonin under 
hypoxic conditions by blotting with HIF-1α or tubulin antibodies. E) MEL103 cell extracts from normoxia (N) or hypoxia (H) exposed to 
shikonin, N-acetyl cysteine (NAC), deferoxamine (DEF) or in combination as shown, and blotted with HIF-1α antibody. F) Activation of 
ferroxitosis from concurrent inhibition of oxidative phosphorylation and PKM2-dependent glycolysis.  
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described as a selective inhibitor of PKM2 activity and 
treatment of mice with shikonin reduced PKM2-dependent 
lactate production [34, 35]. Based on the reported 
observations that nuclear function of PKM2 requires ERK 
activity [10] and that the RAF-MEK-ERK pathway is 
hyperactive in melanoma [11-13], we hypothesized that 
BRAF and MEK inhibitors may sensitize melanoma cells 
to menadione in hypoxic conditions. Cell viability assays 
from several combinations of these drugs in normoxia 
and hypoxia revealed that MEK inhibitor (trametinib) 
or BRAF inhibitor (vemurafenib) by themselves were 
not cytotoxic (Figure 5A). However, when combined 
with these inhibitors, menadione significantly decreased 
cell viability in hypoxia. BRAF inhibitor was selective 
in sensitizing mutant BRAF (MEL526) but not mutant 
NRAS (MEL103) melanoma cells to menadione. Because 
menadione-mediated ferroxitosis requires maximal 
mitochondrial respiration, it is likely that trametinib and 
vemurafenib inhibit ERK activity and disable the nuclear 
function of PKM2 in sensitizing cells to menadione. In 
agreement with these observations, menadione analog 
shikonin, a known inhibitor of PKM2 [34, 35], was 
sufficient to dramatically reduce the viability of cells in 
hypoxia. If a compromise in PKM2 function is essential 
for sensitizing cells to menadione, we reasoned that PKM2 
depletion should sensitize melanoma cells to menadione 
in hypoxia. Recapitulating the effects of shikonin, PKM2 
knockdown restored the cytotoxic effects of menadione in 
hypoxia (Figure 5B). These results suggest that depletion 
of PKM2 in hypoxia forces cells to utilize mitochondria 
for energy production, thus rendering these cells 
vulnerable to menadione-induced ferroxitosis. Consistent 
with these premises, oxygen consumption measurements 
revealed that unlike menadione, shikonin-induced increase 
in OCR was unaffected by iron chelation (Figure 5C). 
Furthermore, we found that exposure of melanoma cells 
to shikonin reduced the levels of lactate under hypoxic 
conditions (Figure S7). 
Since shikonin is a bifunctional compound that 
inhibits PKM2 and also targets mitochondria, we 
asked whether ferroxitosis induced by shikonin would 
destabilize HIF-1α. Immunoblot assays of melanoma 
cells showed shikonin, but not menadione destabilize 
HIF-1α in hypoxia (Figure 5D). To test whether shikonin-
mediated HIF-1α destabilization is due to available iron 
and enhanced oxygen consumption associated oxidative 
stress, MEL103 cells were treated with iron chelator, 
N-acetyl cysteine (NAC), or a combination of these 
agents, and the effects of shikonin on HIF-1α stability in 
hypoxia was assessed. Although iron chelation or NAC 
was not sufficient to completely negate the effects of 
shikonin, NAC combined with deferoxamine reversed 
HIF-1α destabilization (Figure 5E). 
It has been recognized that mitochondria play a key 
role in the pathophysiology of various diseases including 
cancer [36, 37]. For example, gain of mitochondrial 
mass and capacity are thought to contribute to melanoma 
developing resistance to treatment with BRAF inhibitors 
[15-18]. These reports led to the suggestion that targeting 
oxidative phosphorylation with antidiabetic biguanide may 
delay resistance development to BRAF inhibitors [15]. 
Although high concentrations of biguanide phenformin 
seem to augment the effects of BRAF inhibitor [38], 
clinical benefits of these findings are not yet known. 
Our results demonstrate that menadione specifically 
targets oxidative phosphorylation, which could in turn 
improve the therapeutic efficacy of BRAF and/or MEK 
inhibitors. Recognizing the complexity of both nuclear 
and cytoplasmic functions of PKM2, we propose that 
targeting PKM2-dependent glycolysis and oxidative 
phosphorylation could be a novel therapeutic approach 
for neuroectodermal tumors. Considering that highly 
proliferative tumor cells rely heavily on PKM2 for the 
anabolic and energy requirements, specific targeting of 
PKM2 may have less impact on normal cells. Collectively, 
our findings establish that activation of ferroxitosis in 
the context of PKM2 inhibition will not only inactivate 
oxidative phosphorylation (Figure 5F), but it will also 
serve as feed-forward loop to destabilize HIF-1α and 
presents a novel strategy to combat melanoma.
MATERIALS AND METHODS
Cell culture
Cell lines were maintained at 37 °C in a humidified 
atmosphere at 5% CO2 and grown in RPMI 1640 or 
DMEM growth media (Invitrogen) supplemented with 
10% fetal bovine serum (Sigma), 50 units ml−1 penicillin 
and 50 µg ml−1 streptomycin (Invitrogen). The following 
cell lines were maintained in RPMI 1640: SK23, MEL501, 
MEL526, MEL624. The following cell lines were 
maintained in DMEM: BJ, IMR90, MEL103, MEL187, 
RPMI 8322, VMM39, WM2664. Hypoxic conditions (1% 
O2) were achieved in a Ruskinn in-vivo2 400 hypoxia 
chamber, by supplementing ambient air with balanced N2 
and CO2.
Animal studies
NSG (NOD/scid/IL2Rgnull) mice were bred at IU 
Simon Cancer Center In-Vivo Therapeutic Core facility. 
8 week old male animals were subcutaneously implanted 
with 1 million of MEL526 cells in 100μl serum free media 
into the right hind flank. Tumors were allowed to develop 
for 21 days after which the mice were randomized into 
the control and treatment groups (n=4). Treatments of 
vehicle (DMSO) or MEN (15mg/kg body weight) were 
administered via intraperitoneal injection three times 
a week [39]. Xenograft size was measured three times 
Oncotarget12701www.impactjournals.com/oncotarget
a week with a digital caliper and the ellipsoidal tumor 
volumes were recorded. All procedures were conducted in 
accordance with the principles outlined in the NIH Guide 
for the Care and Use of Laboratory Animals and were 
approved by the Indiana University Institutional Animal 
Care and Use Committee (IACUC).
Cell based assays of viability and ATP 
concentration
Cells were seeded at density of 1 x 104 cells per well 
of a 96 well plate (Corning) in technical triplicates per 
condition. Viability was assayed using resazurin reagent 
(Biotium) in accordance with manufacturer’s protocol. 
ATP and caspase activity were measured using CellTiter-
Glo reagent (Promega). Fluorescent and luminescent 
signals were read on Synergy H1 microplate reader 
(BioTek Instruments).
Cellular Respirometry
Oxygen consumption rate (OCR) of cultured cells 
was measured with an XF24 extracellular flux analyzer 
(Seahorse Bioscience). Cells were seeded at 4 x 104 
cells per well one day before the experiment and all 
experiments were performed at 37°C in a bath solution 
consisting of RPMI:DMEM (1:2) supplemented with 3% 
FBS. Following three baseline OCR measurements, wells 
were sequentially injected with oligomycin, menadione 
or vehicle, 2,4-dinitrophenol, and rotenone + antimycin 
A. Once injected, each compound was present in the bath 
medium for the duration of the experiment. Three OCR 
measurements were performed after each injection. To 
ensure that the culture maintained sufficient oxygenation, 
a 3-minute mix, 2-minute wait cycle occurred prior to each 
3-minute measurement.
Immunoblot analysis
Whole-cell extracts were prepared in urea buffer 
(6 M urea, 100 mM sodium dihydrophosphate, 10 mM Tris 
pH 8). SDS-PAGE was performed using TGX gradient 
gels (Bio-Rad) and transferred onto PVDF (Millipore) 
using TransBlot SD semi-dry transfer apparatus (Bio-Rad) 
as per manufacturer’s guidelines. The blots were probed 
with following antibodies: p21, p53, and PUMA (Santa 
Cruz), HIF-1a (R&D Systems), LC3 (Novus), PKM2 
(Cell Signaling), p62 and tubulin (Sigma). Blot images 
were captured on ImageQuant LAS 4000 digital imaging 
system (GE Healthcare, Piscataway, NJ).
HPLC analysis of total nucleotides
Following treatment, medium was aspirated and the 
cells washed three times with ice-cold PBS. Extraction 
was done by scraping the cells in 180 µl ice-cold 
acetonitrile followed by 420 µl cold water. The soluble 
and precipitated fractions were centrifuged at 16000 g 
for 10 min at –20o C. The supernatant fraction, kept on 
ice, was then gassed with N2 for 30 min to evaporate 
acetonitrile. The pellet was solubilized with 1 N NaOH 
and the protein content analyzed with Coomassie Blue 
assay (Pierce Chemical, Rockford, IL). The column used 
was a 4 µm Nova-Pack C18 cartridge (100 mm by 8 mm 
ID), equipped with a radial compression chamber (Waters, 
Millford, MA). The buffer consisted of 20% acetonitrile, 
10 mM ammonium phosphate and 2 mM PIC-A ion 
pairing reagent (Waters) and was run isocratically at 
2 ml/min (10). Samples were diluted in half and the 
injection volume was 100 µl. A HP Chemstation model 
1100 was used (Hewlett-Packard, Wilmington, DE), and 
the UV detector set at 254 nm. HPLC grade nucleotide 
standards were used to calibrate the signals. They were 
run daily because the retention of the column varied with 
time. Internal standards were added to the samples to test 
recovery. It exceeded 90% for all nucleotides.
siRNA knockdown
Gene knockdown was done using PepMute 
(SignaGen) with custom-made dsiRNA (IDT) based 
on published sequences. Briefly, cells were seeded into 
6-well plates at a density of 3 x 10^5 cells per well. siRNA 
complexes were prepared at 20 nM siRNA in according to 
the manufacturer’s instructions.
shRNA-mediated silencing 
The lentiviral shRNA expression plasmids 
were from Sigma. The shRNAs targeting HIF-1a is 
TRCN0000010819 and ARNT is TRCN0000356097. The 
control shRNA is the pLKO.1 - TRC control (Addgene, 
plasmid 10879). The production of viral particles and 
transduction of target cells was conducted as described at 
Broad Institute webpage. 
Statistical Analysis
The DHE fluorescence plots show F/F0 traces from 
individual cells (thin, grey traces) as well as the average F/
F0 signal (thick, red trace). The average DHE F/F0 traces 
are mean ±SEM. 
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